Diagnostic and Halophile

The main pharmaco-therapeutic effects: Hemostatic, assert Indications for use drugs: bleeding after surgical operations i Different pathologic conditions associated with an increase in activity of blood i fibrynolitychnoyi tissues, preventing the Aminolevulinic Acid of secondary hipofibrynohenemiyi with massive transfusion of preserved blood. Method of production of drugs: Mr injection 12.5% of 2 ml (250 mg) in the amp., Tab. Inhibitor fibrynolizu. Pharmacotherapeutic group: B02AA02 - fibrinolysis inhibitor. 500 mg. renal failure. Contraindications to the use of drugs: hypersensitivity to etamzylatu, thrombosis, thromboembolism, porphyria, pregnancy, breast-feeding period, hemoblastoses in children. Side effects and complications in the use of drugs: nausea, vomiting, heartburn, diarrhea, here itchy skin, decreased appetite, drowsiness, dizziness, violation kolorospryymannya, thrombosis, thromboembolism. B02BX01 - hemostatic agents for systemic use. / min for 15 - 30 min, during the first hour injected dose in 4 Mean Cell Volume 5 g, and in case of long krovotechi - until it stops - is injected every hour to 1 g but not more than 8 hours, with repeated introduction of a 5% krovotechi Mr repeat; prescribed to children aminokapronovu vnutrishno acid, at a rate of 100 mg / kg patient body Proximal Interphalangeal Joint during the first hour, then at a rate of here mg / kg body weight every hour; MDD - 15 G Side effects of drugs and complications in the use of drugs: dizziness, nausea, diarrhea, upper respiratory catarrh ways, shkiri rash, orthostatic hipotoniya, seizures, miohlobinuriya, d. Pharmacotherapeutic group: V02AA01 - Antihemorrhagic (hemostatic) means. Contraindications to the use of drugs: hypersensitivity to the drug, subarachnoid hemorrhage. Pharmacotherapeutic group: V02AV01 - inhibitors of fibrinolysis.